Brief: Senzime Outlicenses Exspiron In Chinese Market
June 19 (Reuters) - Senzime AB (publ) SEZI.ST :
* SENZIME OUTLICENSES EXSPIRON IN THE CHINESE MARKET
* ROYALTY INCOME TO SENZIME IS ESTIMATED TO EXCEED SEK 50
MILLION
DURING CONTRACT PERIOD
* AGREEMENT GRANTS CORESPIRON UP TO 10 YEARS OF
MANUFACTURING AND
SALES RIGHTS FOR SENZIME'S EXSPIRON SYSTEM IN CHINESE MARKET
Source text for Eikon: ID:nMFN3W0K3M
Further company coverage: SEZI.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Senzime AB (publ)
See all newsBrief: Senzime Tetragraph System Receives Anvisa Approval For Sale In Brazil
Brief: Senzime Secures Contract With U.S. Hospital
Brief: Senzime Gets Additional FDA Class II 510(K) Clearance For Tetragraph System
Brief: Senzime's TetraGraph System Contracted On Three GPO Agreements In U.S.
Sweden's Senzime Q1 sales dip on weak US markets, strong krona